Drug Discovery

Companuies to use HitGen’s technology platform and research capabilities toward design, synthesis, and screening of multiple DNA-encoded libraries for Pfizer’s drug discovery efforts

Zosano Pharma signed an agreement with Novo Nordisk to develop a new transdermal presentation of semaglutide, an investigational human GLP-1 analog.

USAMRIID partnership aims to vaccinate troops quickly and protect civilian populations from pandemic threats

Firm paid $12 million up front for rights to Exelixis’ candidates.

Korean firm’s HD203 candidate is already undergoing Phase III evaluation in home territory.

Xanthohumol, a compound found in hops, has important anticancer properties but is also metabolized into a potent phytoestrogen that can promote tumor growth. Xanthohumol derivatives have been shown to have even stronger anticancer properties while avoiding the drawback of being metabolized into a phytoestrogen.

A biomarker of aging has emerged from a study of long-lived worms. The biomarker, a transcriptomic signature, consists of expression data from relatively few...

Alnylam Pharmaceuticals earned a development milestone payment from GlaxoSmithKline (GSK) related to progress in the companies’ collaboration on the use of VaxiRNA™ technology for the production of GSK’s influenza vaccine.

MGA271 is in Phase I studies against solid tumors expressing B7-H3.

Teva's $81.50 per share offer has been accepted by Cephalon's board, which had shunned Valeant's $73 per share proposal.